Pharmacokinetic comparison of sinemet and atamet (Generic Carbidopa/Levodopa): A single-dose study

Movement Disorders

Volumn 11, Issue 4, 1996, Pages 427-430

  Pahwa, R ^a   Marjama, J ^a   McGuire, D ^a   Lyons, K ^a   Zwiebel, F ^b   Silverstein, P ^b   Ward, R ^b   Koller, W C ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Carbidopa levodopa; Generic; Parkinson's disease; Pharmacokinetics

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DYSKINESIA; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; ANTIPARKINSON AGENTS; BIOLOGICAL AVAILABILITY; CARBIDOPA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; METABOLIC CLEARANCE RATE; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; THERAPEUTIC EQUIVALENCY;

EID: 0030038292     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110412     Document Type: Article

References (23)

1. Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 1993;43: 2696-2697.
2. Welty TE, Pickering PR, Hale BC, Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 1992;26:755-777.
3. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Neurology 1990; 40:1641-1643.
4. Nuwer MR, Browne TR, Dodson WE, et al. Generic substitutions for antiepileptic drugs. Neurology 1990;40:1647-1651.
5. A Force on Prescription Drugs. Final Report. Washington, D.C.: Government Printing Office. 1969:36-37.
6. Strom BL. Generic substitution revisited. N Engl J Med 1987;316:1456-1462.
7. Schmidt AM. Procedures for establishing a bioequivalence requirement. Fed Reg 1975;40:26164-26171.
8. Evans MA, Triggs EJ, Broe GA, Saines N. Systemic availability of orally administered L-dopa in the elderly parkinsonian patient. Eur J Clin Pharmacol 1980;17:215-221.
9. Fahn S, Elton RL, and Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease. New York: Macmillan, 1987:153-163.
10. Titus D, August T, Yeh K, Eisenhandler R, Bayne W, Musson D. Simultaneous high-performance liquid chromatographic analysis of carbidopa, levodopa and 3-O-methyldopa in plasma and carbidopa, levodopa and dopamine in urine using electrochemical detection. J Chromatogr 1990;584:87-100.
11. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. Philadelphia: Lea and Febiger, 1984.
12. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: interand intrarater reliability assessment. Mov Disord 1994;9: 390-394.
13. Morgan JP, Bianchine JR, Spiegel HE, Rivera-Calimlin L, Hersey RM. Metabolism of levodopa in patients with Parkinson's disease. Arch Neurol 1971;25:39-44.
14. Andersson I, Granerus AK, Jagenburg R, Svanborg A. Intestinal decarboxylation of orally administered L-DOPA. Acta Med Scand 1975;198:415-420.
15. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 1984;310:483-488.
16. Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987; 10:527-537.
17. Leon AS, Spiegel HE. The effect of antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol 1972;12:263-267.
18. Morgan JP, Rivera-Alimlin L, Messina FS, Sundaresan PR, Trabert N. Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 1975;25:1029-1034.
19. Algeri S, Cerletti C, Curcio M, et al. Effect of anticholinergic drugs on gastrointestinal absorption of L-DOPA in rats and man. Eur J Pharmacol 1976;35:293-299.
20. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa: clinical implications. In: Koller WC, ed. Handbook of Parkinson's disease, 2d ed. New York, NY: Marcel Dekker, 1993:411-431.
21. Pahwa R, Lyons K, Marjama J, et al. Clinical experience with generic carbidopa/levodopa (G-L) in patients with Parkinson's disease (PD) [Abstract]. Neurology 1994;44:A244.
22. Nutt JG, Carter JH, Woodward WR. Long-duration rezsponse to levodopa. Neurology 1994;44(suppl 2):A163.
23. Hauser RA, Olanow CW, Koller WC. Time course of washout of symptomatic medication in Parkinson's disease. Neurology 1994;44(suppl 2):A259.